0000905148-24-000774.txt : 20240221 0000905148-24-000774.hdr.sgml : 20240221 20240221162030 ACCESSION NUMBER: 0000905148-24-000774 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240220 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRUNK GERALD A CENTRAL INDEX KEY: 0001380226 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41854 FILM NUMBER: 24659818 MAIL ADDRESS: STREET 1: C/O MDS CAPITAL STREET 2: 245 FIRST ST., STE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: enGene Holdings Inc. CENTRAL INDEX KEY: 0001980845 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1031 BUSINESS ADDRESS: STREET 1: 4868 RUE LEVY, SUITE 220 CITY: SAINT-LAURENT STATE: A8 ZIP: H4R 2P1 BUSINESS PHONE: (514) 332-4888 MAIL ADDRESS: STREET 1: 4868 RUE LEVY, SUITE 220 CITY: SAINT-LAURENT STATE: A8 ZIP: H4R 2P1 4 1 form4.xml X0508 4 2024-02-20 0001980845 enGene Holdings Inc. ENGN 0001380226 BRUNK GERALD A C/O 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 QUEBEC, CANADA true true false Common Shares 2024-02-20 4 A 0 644965 10 A 993651 I See Notes Common Shares 2024-02-20 4 A 0 155035 10 A 238851 I See Notes Common Shares 1341790 I See Notes Common Shares 44647 I See Notes Common Shares 1077386 I See Notes Common Shares 152974 I See Notes These securities are held by Lumira Ventures IV, L.P. ("Lumira IV"). These securities are held by Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"). These securities are held by Lumira Ventures III, L.P. ("Lumira III"). These securities are held by Lumira Ventures III (International), L.P. ("Lumira III Int'l"). These securities are held by Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"). These securities are held by Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"). Mr. Brunk is an executive officer of certain entities controlling and/or managing the Lumira Entities. Mr. Brunk disclaims beneficial ownership of the Common Shares held by the Lumira Entities, except to the extent of his pecuniary interest therein, if any. Lumira III and Lumira III Int'l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Capital Investment Management Inc. ("Lumira Mgmt"). Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt. Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. (Continued in following footnote). (Continued from prior footnote). Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co. Mr. Brunk is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt. Each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any. /s/ Gerald Brunk 2024-02-21